weight loss, Compound versions of drugs

Novo Nordisk, Lilly Stocks Are Falling. A Rival Weight-Loss Drug Is on the Way.
Shares of Novo Nordisk and Eli Lilly slipped in premarket trading Wednesday after Roche said it had landed a $5.3 billion deal to develop an obesity-drug candidate.U.S.-listed shares of Novo Nordisk slipped 4.
Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says
(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday.
Compound versions of some weight loss drugs to be restricted
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.
Eli Lilly Expands Horizons: Launching Weight-Loss Drug in Emerging Markets
Eli Lilly is set to launch its popular weight-loss drug in emerging markets, including India, Brazil, and Mexico, by mid-2025 to meet rising global demand. The strategic expansion offers a significant market opportunity due to the high prevalence of obesity in these populous countries.
Eli Lilly takes aim at weight-loss drug copies with new ad campaign
Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off competition from copies of its weight-loss drug.
Pharmalittle: We’re reading about Lilly and Roche weight loss drugs, FDA and compounders, and more
Three U.S. senators are calling on Robert Kennedy Jr. to disclose what he and President Trump discussed with drugmakers
Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
STAT16h
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
CNN on MSN13d
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an ...
Novo Nordisk Stock Falls After Roche Strikes Weight-Loss Deal
Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Shares in Roche rallied in Europe, while ...
Why Eli Lilly Stock Flopped Today
Zeroing in on Eli Lilly, the company is already well established with Zepbound, which should continue to sell briskly as the world waits for a more powerful and efficacious obesity drug to hit the ...
Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...
Amgen: Riding The MariTide Of Monthly Weight Loss
MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...